Cara Therapeutics, Inc. (NASDAQ:CARA) had its target price increased by Raymond James Financial, Inc. from $25.00 to $26.00 in a research report sent to investors on Tuesday morning, StockTargetPrices.com reports. They currently have a market perform rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on the stock. Zacks Investment Research raised shares of Cara Therapeutics from a hold rating to a buy rating and set a $14.00 price objective on the stock in a research note on Wednesday, August 30th. Scotiabank boosted their price objective on shares of Cara Therapeutics from $31.00 to $31.50 and gave the stock an outperform rating in a research note on Tuesday, October 17th. BidaskClub lowered shares of Cara Therapeutics from a buy rating to a hold rating in a research note on Monday, July 31st. HC Wainwright reaffirmed a buy rating and issued a $30.00 target price on shares of Cara Therapeutics in a report on Friday, August 4th. Finally, ValuEngine cut shares of Cara Therapeutics from a hold rating to a sell rating in a report on Wednesday, September 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Cara Therapeutics has an average rating of Buy and a consensus target price of $25.17.

Cara Therapeutics (CARA) traded up $0.37 during trading hours on Tuesday, reaching $13.26. 1,156,810 shares of the company traded hands, compared to its average volume of 1,874,505. Cara Therapeutics has a 1-year low of $8.61 and a 1-year high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). During the same period last year, the company earned ($0.42) EPS. analysts expect that Cara Therapeutics will post -1.84 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Cara Therapeutics, Inc. (CARA) Price Target Raised to $26.00” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/cara-therapeutics-inc-cara-price-target-raised-to-26-00/1694181.html.

In related news, CEO Derek T. Chalmers sold 16,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $12.66, for a total transaction of $202,560.00. Following the completion of the sale, the chief executive officer now directly owns 1,066,292 shares in the company, valued at $13,499,256.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in CARA. Legal & General Group Plc grew its position in Cara Therapeutics by 10.4% during the second quarter. Legal & General Group Plc now owns 7,167 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 678 shares during the period. Fred Alger Management Inc. purchased a new stake in shares of Cara Therapeutics in the second quarter valued at $123,000. Capital Fund Management S.A. purchased a new stake in shares of Cara Therapeutics in the second quarter valued at $171,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Cara Therapeutics in the third quarter valued at $180,000. Finally, Rathbone Brothers plc purchased a new stake in shares of Cara Therapeutics in the second quarter valued at $185,000. Institutional investors own 61.08% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Stock Target Prices

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.